New Haven, Conn.
Went public 8/2/2000 at $13 per share
Filing Range: 6 mil. shares @ $11 to $13
Shares Outstanding: 21.6 mil. shares
Book Manager: Deutsche Banc Alex. Brown/Bear, Stearns & Co.
Inc./Salomon Smith Barney/ Warburg Dillion Read LLC
Company Counsel: Palmer & Dodge
Manager Counsel: Ropes & Gray
Auditor: Arthur Andersen & Co.
Develops drugs specifically for pharmacogenomics. The company is pursing corporate alliances for use of its Clasper technology that enables pharmaceutical partners to identify isogenes, gene variants containing multiple polymorphisms and the corresponding protein isoforms relevant to variable therapeutic response.
Johnson & Johnson Development Corp.
Chase Capital Partners
Connecticut Innovations Inc.
Dresdner Kleinwort Benson Private Equity
Number of Round Amt.
Round # Round Date Stage Investors ($ thousands)
1 04/01/1998 1 Early Stage 750.0
2 07/01/1998 2 Later Stage 1900.0
3 05/01/1999 2 Early Stage 10000.0
4 11/23/1999 1 Later Stage 500.0
5 03/08/2000 6 Expansion 47062.1
6 05/22/2000 1 Later Stage 1560.0
(Data in $ millions)
Total Revenues: $0.6
Net Income: -9.0